Active, Not Recruiting
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
NCT04624633
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +17 more
- Locations
-
- Dana Farber Cancer Institute Boston, Massachusetts, United States